{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:22:17Z","timestamp":1759666937733},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Smoldering multiple myeloma (SMM) is an asymptomatic, intermediate stage positioned between the plasma cell disorders of monoclonal gammopathy of undermined significance and overt multiple myeloma (MM). Although the patients with SMM have a higher risk of progression to MM in comparison to their counterparts with monoclonal gammopathy of undermined significance, their clinical course can be highly variable. The standard of care for SMM, irrespective of the risk status, continues to be observation due to paucity of high-level evidence demonstrating survival or quality-of-life benefit with early intervention. With the expanded 2014 criteria for MM utilizing biomarkers, the subset of SMM patients with 70% to 80% risk of progression at 2 years (ultra-high risk SMM) is now categorized as active MM and treated prior to the development of end-organ damage. After exclusion of this group, patients with approximately 50% risk of progression in 2 years are now considered high-risk SMM, and the value of early treatment in this subset can be established only through clinical trials. Despite its limitations, a recent phase III trial (QuiRedex) has shown survival advantage to using lenalidomide and dexamethasone doublet over observation in high-risk SMM. In this article, we review the evolving concepts in the diagnosis, risk stratification, and management of SMM.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000350","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T01:22:29Z","timestamp":1548811349000},"page":"65-71","source":"Crossref","is-referenced-by-count":16,"title":["Smoldering Multiple Myeloma"],"prefix":"10.1097","volume":"25","author":[{"given":"Prashant","family":"Kapoor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","year":"1980","journal-title":"N Engl J Med"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2010.1713","article-title":"Multiple myeloma precursor disease","volume":"304","year":"2010","journal-title":"JAMA"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrclinonc.2012.128","article-title":"Redefining myeloma","volume":"9","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/ajh.23204","article-title":"Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"87","year":"2012","journal-title":"Am J Hematol"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","year":"2014","journal-title":"Lancet Oncol"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2010.11.008","article-title":"Multiple myeloma precursor disease: current clinical dilemma and future opportunities","volume":"48","year":"2011","journal-title":"Semin Hematol"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"bib10-20230924","first-page":"947","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","year":"2012","journal-title":"Leukemia"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","year":"2013","journal-title":"Leukemia"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"A8607","DOI":"10.1200\/jco.2014.32.15_suppl.8607","article-title":"Modeling the risk of progression in smoldering multiple myeloma","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","year":"2014","journal-title":"Leukemia"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(14)70001-8","article-title":"Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study","volume":"1","year":"2014","journal-title":"Lancet Haematol"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","year":"2006","journal-title":"N Engl J Med"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2014.34","article-title":"Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the national health and nutritional examination survey","volume":"28","year":"2014","journal-title":"Leukemia"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1056\/NEJMc1310911","article-title":"Treatment for high-risk smoldering myeloma","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1158\/1078-0432.CCR-09-1575","article-title":"Prevention of progression in monoclonal gammopathy of undetermined significance","volume":"15","year":"2009","journal-title":"Clin Cancer Res"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","year":"2007","journal-title":"Blood"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine","volume":"47","year":"2001","journal-title":"Clin Chem"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains","volume":"48","year":"2002","journal-title":"Clin Chem"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(03)12457-9","article-title":"Serum test for assessment of patients with Bence Jones myeloma","volume":"361","year":"2003","journal-title":"Lancet"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","year":"2009","journal-title":"Leukemia"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","year":"2008","journal-title":"Blood"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type","volume":"123","year":"2003","journal-title":"Br J Haematol"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib29-20230924","first-page":"110","article-title":"Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells","volume":"148","year":"2009","journal-title":"Br J Haematol"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","year":"2013","journal-title":"Leukemia"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","year":"2018","journal-title":"Nat Commun"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma","volume":"27","year":"2013","journal-title":"Leukemia"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1995.13.1.251","article-title":"Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"13","year":"1995","journal-title":"J Clin Oncol"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1046\/j.1365-2141.1999.01244.x","article-title":"Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma","volume":"104","year":"1999","journal-title":"Br J Haematol"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","year":"2017","journal-title":"Lancet Oncol"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","year":"2016","journal-title":"Leukemia"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood.V124.21.3382.3382","article-title":"PET-CT has major diagnostic value in the evaluation of smoldering multiple myeloma","volume":"124","year":"2014","journal-title":"Blood"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","article-title":"Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study","volume":"54","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","year":"2018","journal-title":"Blood Cancer J"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","year":"2010","journal-title":"Leukemia"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2009.22.2257","article-title":"Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2014.75","article-title":"Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma","volume":"28","year":"2014","journal-title":"Leukemia"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.hoc.2014.06.005","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"28","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s11899-013-0174-1","article-title":"New approaches to smoldering myeloma","volume":"8","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1182\/blood-2013-08-520890","article-title":"Smoldering multiple myeloma requiring treatment: time for a new definition?","volume":"122","year":"2013","journal-title":"Blood"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrclinonc.2013.160","article-title":"Haematological cancer: treatment of smoldering multiple myeloma","volume":"10","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"bib48-20230924","first-page":"95","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2014a randomized study. Myeloma Group of Western Sweden","volume":"50","year":"1993","journal-title":"Eur J Haematol"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/bjc.1996.212","article-title":"A prognostic index for multiple myeloma","volume":"73","year":"1996","journal-title":"Br J Cancer"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma","volume":"82","year":"2000","journal-title":"Br J Cancer"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/sj.leu.2402866","article-title":"Thalidomide as initial therapy for early-stage myeloma","volume":"17","year":"2003","journal-title":"Leukemia"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease","volume":"112","year":"2008","journal-title":"Blood"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma","volume":"27","year":"2013","journal-title":"Leukemia"},{"key":"bib55-20230924","first-page":"239","article-title":"Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect","volume":"118","year":"2011","journal-title":"Br J Haematol"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study","volume":"52","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","year":"2008","journal-title":"Cancer"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib59-20230924","first-page":"1764","article-title":"Treatment for high-risk smoldering myeloma","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","year":"2015","journal-title":"JAMA Oncol"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/bloodadvances.2017005934","article-title":"Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma","volume":"1","year":"2017","journal-title":"Blood Adv"},{"key":"bib62-20230924","first-page":"1763","article-title":"Treatment for high-risk smoldering myeloma","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib63-20230924","first-page":"1764","article-title":"Treatment for high-risk smoldering myeloma","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib64-20230924","first-page":"1764","article-title":"Treatment for high-risk smoldering myeloma","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib65-20230924","first-page":"e183267","article-title":"Assessment of safety and immunogenicity of PVX-410 vaccine with or without lenalidomide in patients with smoldering multiplemyeloma: a nonrandomized clinical trial","volume":"16","year":"2018","journal-title":"JAMA Oncol"},{"key":"bib66-20230924","article-title":"Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma","journal-title":"Blood"},{"key":"bib67-20230924","article-title":"Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130404-201901000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:16:12Z","timestamp":1695532572000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201901000-00010"}},"subtitle":["To Treat or Not to Treat"],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000350","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}